Bosulif
Payments companies reported to CMS as associated with Bosulif. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Bosulif, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Bosulif
These are the largest totals companies reported as associated with Bosulif. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jorge Cortes-Franco | Houston, TX | Hematology & Oncology | $27,102.59 |
| Hagop Kantarjian | Houston, TX | Medical Oncology | $17,600.00 |
| Elias Jabbour | Houston, TX | Hematology & Oncology | $14,690.09 |
| James Mccloskey | Hackensack, NJ | Medical Oncology | $9,379.56 |
| Michael Mauro | New York, NY | Hematology (Internal Medicine) | $4,201.60 |
| Nobuko Hijiya | Memphis, TN | Pediatric Hematology-Oncology | $4,150.00 |
| Ayushi Chauhan | Houston, TX | Hematology & Oncology | $4,000.00 |
| Kendra Sweet | Tampa, FL | Hematology & Oncology | $3,700.00 |
| Daniel Deangelo | Boston, MA | Hematology & Oncology | $3,700.00 |
| Marlise Luskin | Boston, MA | Medical Oncology | $3,700.00 |
Prescribed Bosulif?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.